C
Crinetics Pharmaceuticals
Novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company operates in the biopharmaceutical market, targeting conditions that have limited treatment options. Crinetics serves patients with rare endocrine disorders, such as acromegaly, by developing innovative oral treatments like CRN00808, which is currently in Phase 2 clinical trials. The business model focuses on advancing drug candidates through clinical trials and obtaining regulatory approvals to bring these therapies to market. Revenue is generated through the commercialization of approved drugs and potential partnerships or licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2018
Open roles
Crinetics Pharmaceuticals in the San Diego ecosystem
The Crinetics Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
National Eye Institute
Series A6 investors entered at this stage
Series B and later12 investors entered at this stage
- ACAdage Capital
- ECEcoR1 Capital
- INInvus
Janus Henderson Investors
OrbiMed- DMDriehaus Capital Management
- GIGordonMD Global Investment
- FMFirst Light Asset Management
- PBParadigm BioCapital
Perceptive Advisors- RCRock Springs Capital
RA Capital Management
Source: Dealroom Talent Intelligence.
Patents
46 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Crinetics Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Vertex acquires Crinetics for $10.0B (September 2026)



